*LONGEVERON® ANNOUNCES NATURE MEDICINE PUBLICATION OF RESULTS OF PHASE 2A CLINICAL TRIAL EVALUATING LAROMESTROCEL (LOMECEL-B™) IN ALZHEIMER’S DISEASE
*LONGEVERON INC - LAROMESTROCEL FIRST CELLULAR THERAPY TO RECEIVE FDA RMAT DESIGNATION FOR ALZHEIMER'S
*LONGEVERON INC - TRIAL ACHIEVED PRIMARY SAFETY AND SECONDARY EFFICACY ENDPOINTS
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 11-MAR-202512:30:00.797 GMT